Report : South & Central America Coagulation Analyzers Market Forecast to 2028 - COVID-19 Impact and Regional Analysis by Product (Clinical Laboratory Analyzers and Point-of-care Testing Analyzers), Test (Prothrombin Time Testing, Fibrinogen Testing, Activated Clotting Time Testing, Activated Partial Thromboplastin Time Testing, D-Dimer Testing, Platelet Function Tests, Anti-Factor XA Tests, Heparin and Protamine Dose Response Tests for ACT, and Others), Technology (Optical Technology, Mechanical Technology, Electrochemical Technology, and Other Technologies), and End Users (Hospitals, Clinical Laboratories, Point-of-Care Testing, and Others)
At 6.1% CAGR, the South & Central America Coagulation Analyzers Market is speculated to be worth US$ 380.05 million by 2028, says Business Market Insights
According to Business Market Insights’ research, the South & Central America coagulation analyzers market was valued at US$ 266.50 million in 2022 and is expected to reach US$ 380.05 million by 2028, registering a CAGR of 6.1% from 2022 to 2028. Increasing prevalence of blood disorders and rising cardiovascular diseases are the critical factors attributed to the South & Central America coagulation analyzers market expansion.
A coagulation analyzer is a device that measures and evaluates the speed of clot formation or clot coagulation. It provides a fast, simple way to measure blood platelet levels and thrombolin and thromboplastin levels accurately. Furthermore, rising incidence of blood disorders is likely to favor market growth. According to the World Federation of Hemophilia, Brazil, is the third largest population of patients with hemophilia, smaller only than that in the United States and in the People’s Republic of China. The Brazilian government has been working hard to increase the supply of quality blood products in sufficient quantities to ensure proper treatment of these individuals. Thus, the increasing prevalence of blood disorders is driving the coagulation analyzers market growth.
On the contrary, high costs and stringent regulations associated with coagulation analyzers hampers the South & Central America coagulation analyzers market.
Based on product, the South & Central America coagulation analyzers market is segmented into clinical laboratory analyzers and point-of-care testing analyzers. The clinical laboratory analyzer segment held 67.9% share of South & Central America coagulation analyzers market in 2022, amassing US$ 181.01 million. It is projected to garner US$ 249.24 million by 2028 to expand at 5.5% CAGR during 2022–2028.
Based on test, the South & Central America coagulation analyzers market is segmented into prothrombin time testing, fibrinogen testing, activated clotting time testing, activated partial thromboplastin time testing, d-dimer testing, platelet function tests, anti-factor xa tests, heparin and protamine dose response tests for act, and others. The prothrombin time testing segment held 52.9% share of South & Central America coagulation analyzers market in 2022, amassing US$ 141.08 million. It is projected to garner US$ 201.25 million by 2028 to expand at 6.1% CAGR during 2022–2028.
Based on technology, the South & Central America coagulation analyzers market is segmented into optical technology, mechanical technology, electrochemical technology, and other technologies. The optical technology segment held 60.8% share of South & Central America coagulation analyzers market in 2022, amassing US$ 162.11 million. It is projected to garner US$ 233.12 million by 2028 to expand at 6.2% CAGR during 2022–2028.
Based on end users, the South & Central America coagulation analyzers market is segmented into hospitals, clinical laboratories, point-of-care testing, and others. The clinical laboratories segment held 59.5% share of South & Central America coagulation analyzers market in 2022, amassing US$ 158.66 million. It is projected to garner US$ 228.73 million by 2028 to expand at 6.3% CAGR during 2022–2028.
Based on country, the South & Central America coagulation analyzers market has been categorized into the Brazil, Argentina, and the Rest of the South & Central America. Our regional analysis states that the Rest of South & Central America captured 38.4% share of South & Central America coagulation analyzers market in 2022. It was assessed at US$ 102.42 million in 2022 and is likely to hit US$ 145.43 million by 2028, exhibiting a CAGR of 6.0% during the forecast period.
Key players dominating the South & Central America coagulation analyzers market are Abbott Laboratories; Danaher Corp; F. Hoffmann-La Roche Ltd; Horiba Ltd.; Nihon Kohden Corp; Shenzhen Mindray Bio-Medical Electronics Co., Ltd.; Siemens Healthcare GmbH; Sysmex Corporation; and Thermo Fisher Scientific Inc, among others.
- In March 2022; Mindray Launched the BC-700 Series, a Compact, Integrated CBC & ESR Hematology Analyzer for Small-to-mid Sized Labs. It incorporates both complete blood count (CBC) and erythrocyte sedimentation rate (ESR) tests.
Contact Us
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email id: sam@businessmarketinsights.com